At Senti Bio, we are developing therapies to fight challenging diseases. Our product candidate pipeline reflects how we are undertaking this battle —by using our gene circuit platform technologies.
Pursuing an Unmet Need in the Treatment of AML
SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow transplant.
Logic Gated Allogeneic CAR-NK Cell Therapy for AML
The unique product profile of SENTI-202 has the potential to drive towards a cure for AML without the need for a bone marrow transplant by enabling killing of diverse AML cells while sparing healthy stem cells that regenerate the blood and the immune systems.
Pursuing an Unmet Need in the Treatment of HCC
SENTI-301 is designed to target glypican 3, or GPC3, which is highly expressed in 70% to 90% of hepatocellular carcinoma (HCC) cases. Our vision is a potential medicine that enhances anti-tumor activity.
Multi-Armed Allogeneic CAR-NK Cell Therapy for HCC
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity.
Pursuing an Unmet Need in the Treatment of CRC
SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal cancer.
Logic Gated Allogeneic CAR-NK Cell Therapy for CRC
The product profile of SENTI-401 has the potential to target a well-known tumor associated antigen, carcinoembryonic antigen (CEA), and widen the therapeutic window by preventing killing when CEA appears on healthy cells that also expresses an epithelial cell Safety Antigen.